Latest News
Affilates of SK Capital Partners (SK Capital), a New York-based private investment firm focused exclusively on the specialty chemicals, materials and pharmaceuticals sectors, have completed the acquisition of Valtris Specialty Chemicals (Valtris) from HIG Capital.
Valtris is a global manufacturer of a comprehensive portfolio of specialty additives and precursors, offering solutions and innovative products to customers around the world. Valtris develops products that provide essential performance properties across a variety of applications including plastics, coatings, adhesives and sealants, pharmaceuticals, flavours and fragrances, and personal care products. The Company operates nine manufacturing locations and employs approximately 700 people across North America,
Affiliates of Stellus Capital Management (Stellus), a specialist in middle market direct lending, have provided senior debt financing and an equity co-investment to support the acquisition of Digimind by Onclusive, a portfolio company of Symphony Technology Group (STG).
Digimind is a specialist in AI-powered social listening platforms and market intelligence software.
Onclusive, headquartered in London, UK, provides industry-leading media monitoring, measurement, and workflow management solutions for public relations and communications. The Company was formed in 2022 after merging Kantar’s Reputation Intelligence businesses with Onclusive, Inc and PRgloo Ltd and rebranding the platform “Onclusive”. Through the acquisition of Digimind,
The proportion of female investment professionals working at private equity (PE) and venture capital (VC) firms across Europe now stands at 20%, according to Level 20, However, that figure falls to just 10% when looking at women employed in senior level positions.
Warburg Pincus has agreed to sell its majority shareholding in Reorg, a global provider of data, analytics and intelligence for the the credit markets, to private equity firm Permira. As part of the transaction, the Reorg team will retain a significant ownership interest.
Bain Capital is targeting $5 billion capital commitments for a new buyout fund focused on the Asia-Pacific region, according to a report by Bloomberg.
ICG, the global alternative asset manager, has completed fundraising for its eighth European Corporate fund (Europe VIII).
The fund held a final close with a total fund size of €8.1 billion, materially in excess of the target of €7.0 billion and exceeding its hard cap, as well as representing a 90% increase in client capital compared to its predecessor vintage, Europe VII.
The fund attracted commitments from over 100 clients, including 33 new clients across Europe, Asia, the Middle East and the US, incorporating a range of investors, such as large public pension schemes, institutional clients and insurance firms.
Virescent Ventures has led a AUD42.5 million Series A funding round in Hysata, a specialist in hydrogen electrolyser technology, on behalf of the Clean Energy Finance Corporation (CEFC).
Kiko Ventures (UK), IP Group Australia, Vestas Ventures, Hostplus, and BlueScope, via its ventures arm BlueScopeX, also participated in the oversubscribed round.
Hysata’s electrolyser operates at 95% system efficiency (41.5 kWh/kg), delivering a giant leap in performance and cost over incumbent technologies, which typically operate at 75% or less. This high efficiency, coupled with the simple approach to mass manufacturing and low supply chain risk puts the company on a path to
IK Partners’s (IK) greenhouse gas (GHG) emissions reduction targets have been validated by the Science Based Targets initiative (SBTi).
These targets are consistent with the levels required to meet the Paris Agreement goals and limit global warming to 1.5°c.
IK has committed to: reducing absolute Scope 1 and Scope 2 GHG emissions by 54% by 2030 from a 2019 base year; and in Scope 3 (portfolio target) achieving 26% of its eligible private equity (PE) investments by invested capital setting SBTi-validated targets by 2026 and 100% by 2040 from a 2021 base year.
IQ Capital and Northern Gritstone have a led a £3.5 million seed funding round in Imperagen, a life sciences company building unique technology to accelerate the development of enzyme biocatalysts.
This represents the company’s first significant external capital raise.
The IP-rich firm is a spinout from the University of Manchester led by serial entrepreneur Dr Andrew Almond, who co-founded Conformetrix, now listed on AIM as C4X Discovery.
Imperagen will use the funding to support the development and validation of its ultra-fast enzyme engineering platform. Its ambition is to initially target its novel enzyme products at the manufacture of
Triple Point Ventures has appointed Manuel Antunes and Jamie Tomalin to its investment team. The new hires bring extensive knowledge and experience within healthtech, climate tech and fintech, bolstering the seed stage VC fund’s team.
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
